A detailed history of Pro Share Advisors LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 45,494 shares of LYEL stock, worth $27,751. This represents 0.0% of its overall portfolio holdings.

Number of Shares
45,494
Previous 38,982 16.71%
Holding current value
$27,751
Previous $56,000 10.71%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.13 - $1.88 $7,358 - $12,242
6,512 Added 16.71%
45,494 $62,000
Q2 2024

Aug 13, 2024

SELL
$1.3 - $3.01 $13,005 - $30,112
-10,004 Reduced 20.42%
38,982 $56,000
Q1 2024

May 08, 2024

BUY
$1.71 - $3.07 $7,130 - $12,801
4,170 Added 9.3%
48,986 $109,000
Q4 2023

Feb 14, 2024

BUY
$1.39 - $2.35 $8,144 - $13,768
5,859 Added 15.04%
44,816 $86,000
Q3 2023

Nov 13, 2023

BUY
$1.45 - $3.35 $342 - $790
236 Added 0.61%
38,957 $57,000
Q2 2023

Aug 10, 2023

BUY
$1.89 - $3.86 $1,984 - $4,053
1,050 Added 2.79%
38,721 $123,000
Q1 2023

May 11, 2023

SELL
$1.97 - $3.58 $10,269 - $18,662
-5,213 Reduced 12.16%
37,671 $88,000
Q4 2022

Feb 02, 2023

BUY
$2.78 - $8.09 $8,237 - $23,970
2,963 Added 7.42%
42,884 $148,000
Q3 2022

Nov 04, 2022

BUY
$5.54 - $8.27 $7,285 - $10,875
1,315 Added 3.41%
39,921 $293,000
Q2 2022

Aug 01, 2022

SELL
$3.68 - $6.8 $52,009 - $96,104
-14,133 Reduced 26.8%
38,606 $251,000
Q1 2022

May 10, 2022

BUY
$5.05 - $7.7 $69,316 - $105,690
13,726 Added 35.18%
52,739 $267,000
Q4 2021

Feb 08, 2022

BUY
$7.13 - $15.19 $278,162 - $592,607
39,013 New
39,013 $302,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $151M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.